Somatostatin

Overview

Somatostatin, also known as somatotropin release-inhibiting factor (SRIF) or growth hormone-inhibiting hormone (GHIH), is a cyclic peptide hormone with broad inhibitory effects on endocrine and exocrine secretion. It was first identified in 1973 by Roger Guillemin and colleagues at the Salk Institute during their search for hypothalamic factors regulating pituitary hormone release. The peptide was initially characterized by its ability to inhibit growth hormone (GH) secretion from anterior pituitary somatotrophs, but subsequent research revealed a remarkably extensive inhibitory profile spanning the hypothalamic-pituitary axis, pancreatic islets, and the entire gastrointestinal tract.

Somatostatin exists in two biologically active forms: SST-14 (a 14-amino-acid cyclic peptide) and SST-28 (a 28-amino-acid N-terminally extended form). Both are derived from a common 116-amino-acid preprosomatostatin precursor through tissue-specific proteolytic processing. SST-14 predominates in the central nervous system and pancreatic delta cells, while SST-28 is the primary form in the gastrointestinal mucosa.

The breadth of somatostatin's inhibitory actions made it an attractive therapeutic target, but the native peptide's extremely short plasma half-life (1-3 minutes) precluded direct clinical use. This limitation drove the development of synthetic somatostatin analogs — octreotide, lanreotide, and pasireotide — which represent one of the most successful examples of peptide drug design in endocrinology. These analogs selectively engage specific somatostatin receptor subtypes with dramatically improved pharmacokinetic profiles and remain cornerstone treatments for acromegaly, neuroendocrine tumors, and other conditions.

Structure

Somatostatin exists in two bioactive forms derived from the same precursor:

SST-14

Sequence: Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys

• Molecular formula: C₇₆H₁₀₄N₁₈O₁₉S₂
• Molecular weight: 1,637.88 Da
• CAS Number: 38916-34-6
• Disulfide bond: Cys3-Cys14 (forms cyclic structure)

SST-28

SST-28 contains the complete SST-14 sequence at its C-terminus preceded by a 14-residue N-terminal extension:

Sequence: Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-[SST-14]

• Molecular weight: ~3,149 Da
• CAS Number: 75037-27-3

The Cys3-Cys14 disulfide bridge in SST-14 constrains the peptide into a cyclic conformation essential for receptor binding. The Phe-Trp-Lys-Thr tetrapeptide motif (residues 7-10) within the ring constitutes the minimal pharmacophore required for biological activity and has served as the template for all clinically approved somatostatin analogs.

Both forms are produced from a single preprosomatostatin gene (SST gene on chromosome 3p28) through tissue-specific post-translational processing by prohormone convertases.

Mechanism of Action

Somatostatin Receptors

Somatostatin signals through five G-protein-coupled receptor subtypes (SSTR1 through SSTR5), all of which are coupled to inhibitory G-proteins (Gi/Go):

Receptor	Primary Distribution	Key Functions
SSTR1	Brain, pancreas, GI tract	Growth hormone inhibition, anti-proliferative
SSTR2	Brain, pituitary, GI tract, pancreas	GH, TSH, gastric acid inhibition; primary target of octreotide
SSTR3	Brain, pancreas	Pro-apoptotic signaling
SSTR4	Brain, lung	Neuromodulation
SSTR5	Pituitary, pancreas, GI tract	Insulin, ACTH inhibition; target of pasireotide

SST-14 binds all five receptor subtypes with approximately equal affinity, while SST-28 shows preferential affinity for SSTR5.

Intracellular Signaling

Upon receptor activation, somatostatin triggers several inhibitory intracellular cascades:

• Adenylyl cyclase inhibition — reduces cAMP levels, suppressing cAMP-dependent secretory pathways
• Potassium channel activation — membrane hyperpolarization reduces cellular excitability and calcium influx
• Voltage-gated calcium channel inhibition — directly reduces calcium entry required for vesicle exocytosis
• Phosphotyrosine phosphatase activation — dephosphorylates growth factor receptor substrates, contributing to anti-proliferative effects
• MAP kinase modulation — receptor subtype-specific effects on ERK1/2 and p38 signaling

Physiological Inhibitory Actions

Somatostatin functions as a broad endocrine and paracrine brake:

Pituitary:

• Inhibits growth hormone secretion (the original defining activity)
• Inhibits thyroid-stimulating hormone (TSH) secretion

Pancreas:

• Inhibits insulin secretion from beta cells
• Inhibits glucagon secretion from alpha cells
• Inhibits pancreatic polypeptide from PP cells

Gastrointestinal tract:

• Inhibits gastric acid (HCl) secretion
• Inhibits pepsin secretion
• Inhibits gastrin, secretin, cholecystokinin (CCK), motilin, and vasoactive intestinal peptide (VIP) release
• Reduces splanchnic blood flow
• Slows gastric emptying and intestinal motility
• Inhibits gallbladder contraction and bile secretion

Research Summary

Area of Study	Key Finding	Notable Reference
Discovery	Identification of SRIF as a 14-amino-acid hypothalamic peptide inhibiting GH release	Brazeau et al., Science, 1973
SST-28 identification	Characterization of the 28-amino-acid extended form predominant in gut	Pradayrol et al., FEBS Letters, 1980
Receptor cloning	Cloning and characterization of five somatostatin receptor subtypes (SSTR1-5)	Yamada et al., Proceedings of the National Academy of Sciences, 1992-1993
Acromegaly treatment	Octreotide normalized GH and IGF-1 levels in acromegalic patients	Lamberts et al., New England Journal of Medicine, 1985
Neuroendocrine tumors	Octreotide LAR slowed tumor progression in metastatic midgut NETs (PROMID trial)	Rinke et al., Journal of Clinical Oncology, 2009
Carcinoid syndrome	Somatostatin analogs controlled flushing and diarrhea in carcinoid syndrome	Kvols et al., New England Journal of Medicine, 1986
Cushing's disease	Pasireotide (multi-receptor SSA) reduced cortisol in Cushing's disease	Colao et al., New England Journal of Medicine, 2012
Variceal bleeding	Octreotide reduced portal pressure and variceal hemorrhage	Burroughs et al., Hepatology, 1990
Peptide receptor radionuclide therapy	Radiolabeled SSAs (DOTATATE) for targeted radiotherapy of SSTR-positive tumors (NETTER-1 trial)	Strosberg et al., New England Journal of Medicine, 2017

Applications

Synthetic Somatostatin Analogs

The native peptide's 1-3 minute half-life necessitated the development of metabolically stable analogs:

Octreotide (Sandostatin):

• Eight-amino-acid cyclic peptide retaining the Phe-Trp-Lys-Thr pharmacophore
• Half-life: ~90 minutes (subcutaneous); LAR depot formulation provides 4-week duration
• Selective for SSTR2 and SSTR5
• Approved for acromegaly, carcinoid syndrome, VIPomas, and variceal bleeding

Lanreotide (Somatuline):

• Eight-amino-acid analog with similar receptor selectivity to octreotide
• Autogel depot formulation for monthly injection
• Approved for acromegaly and gastroenteropancreatic NETs

Pasireotide (Signifor):

• Multi-receptor somatostatin analog with high affinity for SSTR1, 2, 3, and 5
• Approved for Cushing's disease and acromegaly
• Enhanced SSTR5 binding enables ACTH suppression

Diagnostic Applications

• Somatostatin receptor scintigraphy (OctreoScan) — radiolabeled octreotide (¹¹¹In-pentetreotide) for imaging SSTR-positive neuroendocrine tumors
• ⁶⁸Ga-DOTATATE PET/CT — high-resolution functional imaging of neuroendocrine tumors
• Peptide receptor radionuclide therapy (PRRT) — ¹⁷⁷Lu-DOTATATE (Lutathera) for treatment of SSTR-positive metastatic NETs

Context in Growth Hormone Research

Somatostatin's inhibition of GH release places it in direct opposition to the growth hormone-releasing peptides studied elsewhere in the peptide research community. Compounds such as Sermorelin, CJC-1295, GHRP-6, GHRP-2, and Ipamorelin all stimulate GH release through mechanisms that must overcome somatostatin's tonic inhibitory tone. Understanding somatostatin physiology is therefore essential to understanding the pharmacology of GH secretagogues.

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. Always consult a qualified healthcare professional.

Native somatostatin-14 has a plasma half-life of only 1-3 minutes, making it impractical for chronic therapy. Clinical applications use synthetic analogs with improved pharmacokinetics.

Compound	Indication	See Article
Octreotide (Sandostatin)	Acromegaly, carcinoid, NETs	Octreotide
Lanreotide (Somatuline)	Acromegaly, GEP-NETs	Lanreotide
Pasireotide (Signifor)	Cushing's disease, acromegaly	Pasireotide

As an endogenous hormone, native somatostatin is primarily studied as a physiological regulator and through its receptor-targeted analogs rather than administered directly in clinical practice.

Related Compounds

• Sermorelin — a GHRH analog that stimulates GH release, counteracted by somatostatin's inhibitory tone
• CJC-1295 — a long-acting GHRH analog; its efficacy depends on overcoming somatostatin pulsatility
• GHRP-6 — a growth hormone-releasing peptide that partially functions by suppressing somatostatin release
• Ipamorelin — a selective GHS-R1a agonist releasing GH in the context of somatostatin regulation
• Insulin — a pancreatic hormone whose secretion is inhibited by somatostatin from neighboring delta cells
• VIP — a gastrointestinal neuropeptide whose release is suppressed by somatostatin